Related Experiment Video
Updated: May 26, 2026
08:58
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Developing a drug library for smart pumps in a pediatric intensive care unit
Silvia Manrique-Rodríguez1, Amelia Sánchez-Galindo, Cecilia M Fernández-Llamazares
1Pharmacy Department, Gregorio Marañón General and Teaching Hospital, Madrid, Spain.
Artificial Intelligence in Medicine
|January 10, 2012
Summary
Smart pump drug libraries significantly reduce medication errors in pediatric intensive care units (PICUs). This technology, with high nurse acceptance, effectively intercepts dangerous programming mistakes during intravenous drug administration.
Area of Science:
- Medical device technology
- Patient safety
- Pediatric critical care
Background:
- Intravenous medication administration poses serious risks, especially in critically ill children.
- Smart pumps with drug libraries offer a solution to prevent programming errors by setting dose limits.
- Drug libraries provide alerts for dosages exceeding or falling below pre-determined safe limits.
Purpose of the Study:
- To detail the development process of a drug library for a pediatric intensive care unit (PICU).
- To identify key factors crucial for preventing medication programming errors.
- To evaluate the effectiveness and acceptance of smart pump technology in a PICU setting.
Main Methods:
- A multidisciplinary team (clinical pharmacist, PICU pediatrician, chief nurse) developed the drug library over seven months.
- A literature review informed the selection of standard concentrations and safety limits for high-risk intravenous drugs.
- Alaris® syringe pumps and Guardrails® CQI v4.1 software were utilized for library implementation and data reporting.
Main Results:
- The developed drug library covered 108 drugs, with 85% compliance observed.
- Nurses reported high acceptance, with 94% recommending the technology for other units.
- Potentially harmful infusion programming errors were intercepted within nine months of implementation.
Conclusions:
- Customizing drug libraries for specific hospital units is vital for successful implementation.
- Smart pump technology, when implemented in a PICU, effectively intercepts infusion-related programming errors.
- The study demonstrates the value of smart pumps in enhancing patient safety during critical care.
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).